Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 121Lymphoma, Mantle-Cell 68Lymphoma, Large B-Cell, Diffuse 40Lymphoma, Non-Hodgkin 31Lymphoma, Follicular 30Waldenstrom Macroglobulinemia 29Lymphoma 29Recurrence 23Lymphoma, B-Cell 22Lymphoma, B-Cell, Marginal Zone 19Neoplasms 16Leukemia 14Leukemia, B-Cell 10Multiple Myeloma 9Bronchiolitis Obliterans Syndrome 9Leukemia, Lymphoid 8Burkitt Lymphoma 8Hematologic Neoplasms 7Leukemia, Myeloid, Acute 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Hodgkin Disease 5Leukemia, Prolymphocytic 4Graft vs Host Disease 4Lymphoproliferative Disorders 3Lymphatic Diseases 3Leukemia, Hairy Cell 3Immunoproliferative Disorders 3Immune System Diseases 3Hematologic Diseases 3Chromosome 17 deletion 3

Interventions

avapritinib 5midostaurin 4masitinib 2Imatinib Mesylate 2sarilumab 1ripretinib 1obatoclax 1nilotinib 1ibrutinib 1dexamethasone acetate 1dexamethasone 21-phosphate 1denileukin diftitox 1auricularum 1Thalidomide 1Ranitidine 1Phlebotomy 1Interviews as Topic 1Ibuprofen 1Everolimus 1Diphenhydramine 1Dexamethasone 1Denosumab 1Dasatinib 1Cladribine 1Calcium Dobesilate 1Brentuximab Vedotin 1Azacitidine 1Acetaminophen 1AK002 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mastocytosis, Systemic × ibrutinib × Clear all
NCT02415608 2018-09-20

Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis

Stanford University

Phase 2 Terminated
4 enrolled 14 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡